Home / Deep Research / Alpha-gal Syndrome

Alpha-gal Syndrome

1. Disease Information

2026-07-05
Falcon MONDO:0100001 Model: Edison Scientific Literature 57 citations

1. Disease Information

Overview

Alpha-gal syndrome (AGS) is an IgE-mediated allergic disorder characterized by delayed hypersensitivity reactions to the oligosaccharide galactose-alpha-1,3-galactose (alpha-gal), a carbohydrate found in non-primate mammalian tissues, meat products, dairy, gelatin, and mammalian-derived medications (wilson2024tickbitesige pages 1-3, macdougall2022themeatof pages 1-2). Unlike conventional food allergies targeting proteins, AGS is uniquely directed against a carbohydrate epitope and features a characteristic delay of 2–6 hours between allergen ingestion and symptom onset (wilson2024tickbitesige pages 1-3, vazrodrigues2022currentandfuture pages 1-2). The syndrome was first recognized when patients experienced severe anaphylaxis upon infusion of cetuximab, a monoclonal antibody produced in mouse-derived cell lines, and subsequent investigation linked the sensitization to tick bites (propst2025alphagalsyndromeand pages 1-2). AGS is now recognized as the tenth most common food allergy in the United States, with an estimated 450,000 cases nationally (choudhary2025singlecellmrnaanalysis pages 1-2).

Key Identifiers

  • ICD-10: The MeSH term "red meat allergy" (C000655084) is associated with AGS in clinical trial registrations (NCT06268717 chunk 2). A dedicated ICD-10 code was not widely available until recently; AGS lacked a dedicated diagnostic billing code, contributing to underdiagnosis (wilson2024tickbitesige pages 3-4).
  • OMIM: No dedicated OMIM entry (AGS is an acquired, not a Mendelian, condition).
  • MONDO: Not indexed.
  • Synonyms: Red meat allergy, mammalian meat allergy, alpha-gal allergy, tick-induced meat allergy, galactose-alpha-1,3-galactose allergy.

Data Source

Information is derived primarily from aggregated disease-level resources (clinical reviews, cohort studies, case series) and clinical trial registrations, with single-cell profiling data from individual patient samples.

2. Etiology

Disease Causal Factors

AGS is an acquired immunological disorder. The primary causal factor is sensitization to alpha-gal through bites of hard-bodied (ixodid) ticks, particularly Amblyomma americanum (lone star tick) in the southeastern United States (wilson2024tickbitesige pages 1-3, macdougall2022themeatof pages 2-4). Tick saliva contains alpha-gal residues on glycoproteins and glycolipids and other biomolecules such as prostaglandin E2, which, upon injection into the host during blood feeding, initiate an IgE-mediated immune response to alpha-gal (vazrodrigues2022currentandfuture pages 1-2). Tick saliva interferes with dendritic cell maturation, suppressing pro-inflammatory Th1/Th17 responses while promoting Th2 pro-allergic responses, which drives the production of alpha-gal-specific IgE by B cells (macdougall2022themeatof pages 2-4).

The alpha-gal carbohydrate is synthesized by the enzyme alpha-1,3-galactosyltransferase (encoded by the GGTA1 gene), which is functional in non-primate mammals but is a non-functional pseudogene in humans due to mutations accumulated over approximately 28 million years of evolution (cabezascruz2019environmentalandmolecular pages 1-2, wilson2024tickbitesige pages 3-4). This makes alpha-gal a foreign antigen highly immunogenic in humans (kepley2025tickedoffallergic pages 1-2).

Risk Factors

Genetic/Intrinsic Risk Factors: - ABO blood type: Persons with blood type B are approximately one-fourth as likely to have AGS compared to blood type O, as the B-antigen is structurally similar to alpha-gal (sharing terminal galactoses connected by alpha-1,3 bonds) and may confer cross-protective immune tolerance (taylor2024intrinsicriskfactors pages 6-8, wilson2024tickbitesige pages 3-4). Individuals with A and O blood types have higher AGS risk (macdougall2022themeatof pages 4-5). - Race/ethnicity: White individuals showed higher seroconversion rates (6.6%) compared to Black (1.0%) and Hispanic (1.5%) populations in a military cohort, which may be partly attributable to differential distribution of protective B blood type alleles (taylor2024intrinsicriskfactors pages 6-8). - Atopy and childhood allergies: AGS case patients were significantly more likely to report childhood allergies that resolved in adulthood, family history of AGS (OR 8.33), family history of food allergies (OR 2.70), and vitamin D deficiency (taylor2024intrinsicriskfactors pages 1-3, taylor2024intrinsicriskfactors pages 5-6). - Heightened insect bite reactivity: Longer healing times for insect bites or stings (taylor2024intrinsicriskfactors pages 1-3). - Sex: Male sex has been identified as a risk factor for both sensitization and clinical AGS, though in case-control analyses, sex did not always reach significance when accounting for occupational exposure (macdougall2022themeatof pages 4-5).

Environmental Risk Factors: - Tick exposure: The predominant risk factor. 86% of diagnosed AGS patients report tick bite history (binder2023clinicalandlaboratory pages 1-1). Frequent tick exposure confers greater sensitization risk than single prolonged exposure (propst2025alphagalsyndromeand pages 1-2). - Outdoor occupation/activities: Forestry workers, rural workers, military personnel in outdoor occupations, hunters, and gardeners have elevated sensitization rates (nalcacı2024mysteriousallergycaused pages 6-7). Infantry/law enforcement personnel showed 12.7% seroconversion vs. 1.2% for administrative personnel (Ching et al. 2024). - Rural residence: Higher sensitization rates in rural versus urban areas (macdougall2022themeatof pages 4-5). - Cofactors: Alcohol consumption and exercise can potentiate allergic responses and lower the threshold for reactions (binder2023clinicalandlaboratory pages 2-2, propst2025alphagalsyndromeand pages 2-3).

Protective Factors

  • Blood type B: Expression of the B-antigen is the best-studied non-tick protective factor. Structural similarity between alpha-gal and B-blood group antigen may provide cross-reactive immune tolerance (wilson2024tickbitesige pages 3-4).
  • IgG4 antibodies: Higher levels of alpha-gal-specific IgG4 are associated with tolerance; AGS patients show reduced IgG4 compared to non-allergic alpha-gal-sensitized individuals (macdougall2022themeatof pages 2-4, carson2022where’sthebeef? pages 3-4).
  • Tick avoidance: Long-term tick bite avoidance (1–2 years) may allow tolerance recovery and permit meat reintroduction (vazrodrigues2022currentandfuture pages 6-7).

Gene–Environment Interactions

The interplay between the non-functional human GGTA1 pseudogene (making alpha-gal foreign) and environmental tick bite exposure is the fundamental gene–environment interaction underlying AGS. Furthermore, intrinsic genetic factors influencing immune polarization (Th2 tendency, atopic constitution) interact with tick salivary components to determine whether an individual develops clinical AGS or remains asymptomatically sensitized (taylor2024intrinsicriskfactors pages 1-3, taylor2024intrinsicriskfactors pages 5-6).

3. Phenotypes

The clinical presentation of AGS is diverse and often delayed, making diagnosis challenging. The following table summarizes major phenotypic features:

Table (click to expand)
Phenotype/Symptom HPO Term Frequency Onset Timing Severity Notes
Urticaria / hives HP:0001025 Very common (about 60–80%) Typically 2–6 hours after ingestion of mammalian meat/products Mild to severe Most common cutaneous manifestation; often part of delayed multisystem reactions in AGS (binder2023clinicalandlaboratory pages 2-2, vazrodrigues2022currentandfuture pages 1-2, binder2023clinicalandlaboratory pages 1-1)
Anaphylaxis HP:0011844 Common (up to about 60%) Usually delayed 2–6 hours after exposure Severe / life-threatening Can involve ≥2 organ systems; 75% of patients in one US cohort met anaphylaxis criteria (vazrodrigues2022currentandfuture pages 1-2, binder2023clinicalandlaboratory pages 2-2, binder2023clinicalandlaboratory pages 1-1)
Angioedema HP:0100665 Common Typically 2–6 hours after ingestion Moderate to severe Frequently accompanies urticaria and may occur with broader systemic reactions (binder2023clinicalandlaboratory pages 2-2, vazrodrigues2022currentandfuture pages 1-2)
Gastrointestinal symptoms (abdominal pain, nausea, vomiting, diarrhea) HP:0002027, HP:0002018, HP:0002013, HP:0002014 Common (about 59–79%) Typically 2–6 hours after ingestion Mild to severe Can present in isolation without skin findings; often overlaps with IBS-like symptoms and may be under-recognized (binder2023clinicalandlaboratory pages 2-2, propst2025alphagalsyndromeand pages 1-2, macdougall2022themeatof pages 10-11)
Pruritus HP:0000989 Very common Typically 2–6 hours after ingestion Mild to moderate Common early allergic manifestation; often accompanies hives or angioedema (vazrodrigues2022currentandfuture pages 1-2, nalcacı2024mysteriousallergycaused pages 1-2)
Cardiovascular symptoms HP:0001626 Uncommon Variable; may occur during systemic reactions or in association studies Potentially severe Reported associations include noncalcified plaque, obstructive coronary artery disease, and STEMI; evidence includes sensitization/cardiovascular links beyond classic food reactions (wilson2024tickbitesige pages 1-3, propst2025alphagalsyndromeand pages 7-8)
Hypotension / shock HP:0002615 Uncommon During anaphylaxis Severe Represents severe systemic involvement and requires prompt epinephrine-based management (vazrodrigues2022currentandfuture pages 6-7, leder2024perioperativeconsiderationsin pages 3-5)
Respiratory distress HP:0002098 Less common During anaphylaxis Severe Part of the anaphylactic cascade; more concerning in severe systemic AGS reactions (vazrodrigues2022currentandfuture pages 6-7, NCT06268717 chunk 2, NCT07611435 chunk 1)

Table: This table summarizes the major clinical phenotypes of Alpha-gal Syndrome, including suggested HPO terms, approximate frequencies, timing, severity, and clinically useful notes. It is useful for structuring phenotype annotations in a disease knowledge base.

Key Phenotypic Features

Suggested HPO Terms

4. Genetic/Molecular Information

Causal Gene: GGTA1

AGS is not a Mendelian genetic disease but rather an acquired immunological condition. However, the evolutionary loss of GGTA1 function in humans is the molecular prerequisite. The GGTA1 gene encodes alpha-1,3-galactosyltransferase (HGNC:4319), the enzyme responsible for synthesizing the alpha-gal epitope on glycoproteins and glycolipids. In humans and Old World primates, GGTA1 is a pseudogene that produces only truncated transcripts lacking the two catalytic exons needed for enzyme activity (cabezascruz2019environmentalandmolecular pages 1-2). At least two separate mutations account for this loss of function, accumulated over ~28 million years (wilson2024tickbitesige pages 3-4). Non-primate mammals, New World monkeys, and platyrrhine primates retain a functional GGTA1 gene (carson2022where’sthebeef? pages 1-3).

Immunoglobulin Gene Rearrangements

Single-cell analysis has revealed that alpha-gal-specific IgE is secreted by a heterogeneous population of B cells, including CCR6-proficient memory B cells and CCR6-deficient plasmablasts/plasma cells. Individual B cells were found to express IgE-secreting transcripts alongside other immunoglobulin classes (IgA, IgG, IgM), suggesting a unique pattern of Ig gene arrangements and class switching (choudhary2025singlecellmrnaanalysis pages 1-2, choudhary2025singlecellmrnaanalysis pages 14-17).

No Pathogenic Variants or Chromosomal Abnormalities

AGS does not involve pathogenic variants in the traditional clinical genetics sense. The disease is acquired through environmental exposure (tick bites), and susceptibility is modulated by ABO blood group genotype and atopic predisposition rather than by mutations in a single causative gene.

5. Environmental Information

Environmental Factors

  • Tick bites are the primary environmental trigger, with multiple tick species implicated globally (see Tick Species table below).
  • Medications and medical products containing alpha-gal represent significant iatrogenic exposure risks, including heparin, gelatin-containing vaccines, cetuximab, surgifoam, lidocaine patches, and bioprosthetic heart valves (macdougall2022themeatof pages 10-11, leder2024perioperativeconsiderationsin pages 3-5, commins2020diagnosis&management pages 16-18).

Lifestyle Factors

Infectious Agents

Tick bites are the sensitizing event. The following table summarizes tick species associated with AGS worldwide:

Table (click to expand)
Tick Species Geographic Region/Country Reference
Amblyomma americanum Southeastern United States; Coastal Atlantic states, USA (wilson2024tickbitesige pages 3-4, sharma2024tickbiteinducedalphagal pages 1-2, platts‐mills2025theimmunologyof pages 6-8)
Ixodes holocyclus Australia; especially eastern coastal Australia (wilson2024tickbitesige pages 3-4, sharma2024tickbiteinducedalphagal pages 1-2, platts‐mills2025theimmunologyof pages 6-8)
Ixodes ricinus Europe (including Sweden, Germany, broader established range) (vazrodrigues2022currentandfuture pages 1-2, wilson2024tickbitesige pages 3-4, sharma2024tickbiteinducedalphagal pages 1-2, choudhary2025singlecellmrnaanalysis pages 1-2)
Haemaphysalis longicornis Japan/Asia (vazrodrigues2022currentandfuture pages 1-2, sharma2024tickbiteinducedalphagal pages 1-2, choudhary2025singlecellmrnaanalysis pages 1-2, platts‐mills2025theimmunologyof pages 6-8)
Amblyomma sculptum Brazil (sharma2024tickbiteinducedalphagal pages 1-2, choudhary2025singlecellmrnaanalysis pages 1-2)
Rhipicephalus bursa Europe (sharma2024tickbiteinducedalphagal pages 1-2)
Hyalomma marginatum Europe (sharma2024tickbiteinducedalphagal pages 1-2)
Ixodes scapularis Eastern United States (sharma2024tickbiteinducedalphagal pages 1-2, platts‐mills2025theimmunologyof pages 6-8)
Amblyomma testudinarium Asia (platts‐mills2025theimmunologyof pages 6-8)
Ixodes pacificus Western United States (platts‐mills2025theimmunologyof pages 6-8)

Table: This table summarizes tick species reported in the literature as implicated in alpha-gal sensitization or alpha-gal syndrome across major world regions. It is useful for mapping geographic risk and understanding regional differences in AGS epidemiology.

6. Mechanism / Pathophysiology

Sensitization Phase (Tick Bite → IgE Production)

The causal chain begins with tick attachment and blood feeding. Tick saliva contains alpha-gal on glycoproteins and glycolipids, along with immunomodulatory molecules including prostaglandin E2 (vazrodrigues2022currentandfuture pages 1-2). Tick saliva interferes with dendritic cell maturation, suppressing Th1/Th17 responses while favoring Th2 pro-allergic polarization (macdougall2022themeatof pages 2-4). Antigen-presenting cells (dendritic cells, macrophages, B cells) present alpha-gal to Th2 cells, which produce IL-4 and IL-13, driving B cell class switching to IgE (vazrodrigues2022currentandfuture pages 1-2). Repeated tick bites strengthen the Th2 signal (platts‐mills2025theimmunologyof pages 11-13). Notably, all humans produce natural IgG, IgM, and IgA antibodies to alpha-gal from gastrointestinal bacterial exposure, but IgE production is the pathological consequence of tick-mediated sensitization (wilson2024tickbitesige pages 1-3, carson2022where’sthebeef? pages 3-4).

Effector Phase (Meat Ingestion → Delayed Allergic Reaction)

Upon consumption of mammalian meat, alpha-gal glycolipids cross the intestinal epithelial barrier and are incorporated into chylomicrons in lacteals, entering systemic circulation approximately one hour post-ingestion (platts‐mills2025theimmunologyof pages 11-13). Over 2–6 hours, chylomicrons (300–1000 nm) are progressively metabolized to VLDL and LDL particles (12–25 nm), which carry alpha-gal on their surface glycosylation (platts‐mills2025theimmunologyof pages 11-13). These smaller LDL particles can extravasate through endothelial walls into tissue compartments where they encounter mast cells bearing alpha-gal-specific IgE on FcεRI receptors. Alpha-gal on LDL cross-links surface-bound IgE, triggering mast cell and basophil degranulation and release of histamine, leukotrienes, and tryptase (platts‐mills2025theimmunologyof pages 11-13, branicka2025alphagalsyndrome—aseries pages 4-6). Basophil activation peaks approximately 4 hours after meat consumption, correlating with clinical symptom appearance (macdougall2022themeatof pages 2-4, carson2022where’sthebeef? pages 9-11). AGS patients also show significant differences in lipid metabolism, with delayed lipid processing contributing to the prolonged interval between ingestion and reaction (carson2022where’sthebeef? pages 8-9, kepley2025tickedoffallergic pages 7-8).

Molecular Pathways

  • Th2 immune signaling: IL-4, IL-13 → IgE class switching (GO:0045191)
  • FcεRI signaling: IgE cross-linking → mast cell/basophil degranulation (GO:0038095)
  • Lipid metabolism and chylomicron processing: GO:0034370 (triglyceride-rich lipoprotein particle remodeling)
  • Antigen presentation: Enhanced MHC-II expression (GO:0019882)

Cell Types Involved

Cardiovascular Associations

Alpha-gal sensitization has been associated with noncalcified plaque, obstructive coronary artery disease, and ST-segment-elevated myocardial infarction (propst2025alphagalsyndromeand pages 7-8). Chronic IgE-mediated inflammation from bioprosthetic valve implantation (containing alpha-gal) may contribute to early valve degradation and accelerated coronary artery disease (kuravi2022allergicresponseto pages 1-2, kuravi2022allergicresponseto pages 6-9).

Molecular Profiling

Single-cell analysis (Choudhary & Commins, 2025): Multimodal single-cell RNA transcriptome and surface protein analysis of PBMCs from 18 AGS and 10 control subjects captured 437,770 total cells and identified 43 distinct immune cell clusters (choudhary2025singlecellmrnaanalysis pages 4-5). Key findings include: - Circulating mast cell progenitors (cluster C43) with 53-fold elevated TPSAB1/tryptase and 8-fold elevated KIT expression (choudhary2025singlecellmrnaanalysis pages 8-11) - CD4+-NKT cells predominantly from AGS subjects (96% in cluster C32) linked to Th2 responses (choudhary2025singlecellmrnaanalysis pages 17-18) - 1,141 IgE-secreting cells containing 11,017 IgE transcripts identified (choudhary2025singlecellmrnaanalysis pages 14-17) - Elevated S100A9, IFITM3, and THBS1 across multiple cell types in AGS subjects (choudhary2025singlecellmrnaanalysis pages 17-18) - Enhanced antigen presentation genes: CD52, CXCL16, HLA-DPA1, HLA-DRA, ICAM1, IFITM3, LAP3, THBS1 (choudhary2025singlecellmrnaanalysis pages 8-11)

7. Anatomical Structures Affected

Organ Level

  • Primary: Skin (urticaria, angioedema), gastrointestinal tract (abdominal pain, nausea, vomiting, diarrhea), cardiovascular system (anaphylaxis-associated hypotension)
  • Secondary: Cardiovascular system (noncalcified plaque, coronary artery disease), respiratory system (during anaphylaxis)
  • Body systems: Immune system, integumentary system, digestive system, cardiovascular system, respiratory system

Tissue and Cell Level

  • Skin — dermal mast cells (CL:0000097)
  • Gastrointestinal mucosa — mucosal mast cells, eosinophils (CL:0000771)
  • Vascular endothelium — sites of LDL extravasation and mast cell activation
  • Bone marrow — mast cell progenitors

Subcellular Level

  • Endosomes/lysosomes (GO:0005764) — alpha-gal glycoprotein processing
  • Cell surface (GO:0009986) — FcεRI receptor complexes
  • Secretory granules (GO:0030141) — mast cell/basophil degranulation

UBERON Terms

8. Temporal Development

Onset

Progression

  • Disease course: Episodic, with reactions triggered by exposure to alpha-gal-containing foods or products.
  • Duration: Chronic but potentially reversible. Alpha-gal sIgE generally decreases over time with tick avoidance, though complete resolution was observed in only 1 of 13 patients in longitudinal follow-up (binder2023clinicalandlaboratory pages 8-8). Long-term tick avoidance (1–2 years) may allow tolerance recovery (vazrodrigues2022currentandfuture pages 6-7).
  • Severity modulation: Fattier meals lead to more consistent reactions; exercise, alcohol, and repeated tick bites can increase severity (propst2025alphagalsyndromeand pages 2-3).

9. Inheritance and Population

Epidemiology

  • Estimated prevalence (USA): Approximately 450,000 cases nationally; approximately 2–5 cases per 100,000 persons reported, though county-level estimates suggest much higher prevalence (wilson2024tickbitesige pages 3-4, choudhary2025singlecellmrnaanalysis pages 1-2).
  • Sensitization rates: 22% of North Carolina endoscopy patients; 20.8% of a Tennessee asymptomatic cohort; 35% among German forest workers/hunters (though only 8.6% of the German cohort reported clinical symptoms) (binder2023clinicalandlaboratory pages 2-2, binder2023clinicalandlaboratory pages 2-3).
  • Seroconversion incidence (military): 4.9% seroconversion rate over a mean 3.4-year interval among 2,821 initially seronegative military personnel (Ching et al. 2024).
  • Global distribution: Cases documented on every continent except Antarctica, with highest prevalence in the southeastern United States, Sweden, Australia, South Africa, and Germany (macdougall2022themeatof pages 4-5, wilson2024tickbitesige pages 3-4).
  • Search volume trends: Google search volume for alpha-gal increased by an estimated 627% from 2015 to 2022, with an average annual percent change of 33.78% (Romeiser et al. 2024).

Inheritance Pattern

AGS is not inherited in a Mendelian fashion. It is an acquired immunological condition. However, familial clustering has been observed—AGS patients are 8.33 times more likely to report relatives with AGS (taylor2024intrinsicriskfactors pages 5-6)—which may reflect shared genetic predisposition (atopy, blood type), shared environmental exposures (tick habitat), and increased diagnostic awareness within families.

Population Demographics

10. Diagnostics

Clinical Tests

  • Alpha-gal-specific IgE (sIgE): The primary diagnostic biomarker. Titers ≥0.1 IU/mL (or kU/L) are considered positive, though elevated sIgE alone does not confirm clinical AGS—clinical history is essential (binder2023clinicalandlaboratory pages 2-3, macdougall2022themeatof pages 1-2).
  • Skin prick test (SPT): Wheal and flare responses to alpha-gal-containing extracts (macdougall2022themeatof pages 4-5).
  • Basophil activation test (BAT): Measures CD63 activation on peripheral blood basophils stimulated with mammalian-based extracts; peak activation at ~4 hours post-meat ingestion (vazrodrigues2022currentandfuture pages 1-2, macdougall2022themeatof pages 2-4).
  • Oral food challenge (OFC): The gold standard but carries anaphylaxis risk; double-blind, placebo-controlled food challenges are used in research settings, including novel challenges using alpha-gal knockout pork (NCT06268717 chunk 1, NCT07611435 chunk 1).
  • Serum tryptase: Marker for mast cell degranulation, elevated in only 30% of AGS patients (macdougall2022themeatof pages 4-5).
  • Total IgE: Often elevated in AGS patients.

Emerging Diagnostic Tools

Clinical Criteria

Diagnosis is based on: (1) compatible clinical history of delayed allergic reactions to mammalian meat/products, (2) elevated alpha-gal-specific IgE, and (3) exclusion of alternative diagnoses. No universally standardized diagnostic criteria exist (binder2023clinicalandlaboratory pages 2-3).

Differential Diagnosis

  • Irritable bowel syndrome (for GI-predominant AGS)
  • Chronic spontaneous urticaria
  • Idiopathic anaphylaxis
  • Systemic mastocytosis
  • Non-celiac gluten sensitivity
  • Lactose intolerance
  • Other food allergies

11. Outcome / Prognosis

Mortality and Morbidity

AGS can be life-threatening when anaphylaxis occurs, but mortality data are limited. The primary morbidity includes recurrent allergic reactions, dietary restriction, quality of life impairment, and diagnostic delay (macdougall2022themeatof pages 11-13). AGS is a leading cause of anaphylaxis in southeastern US adults and adolescents (macdougall2022themeatof pages 4-5).

Disease Course

12. Treatment

Pharmacotherapy

Advanced/Experimental Therapeutics

  • Oral immunotherapy (OIT): Case reports show successful beef desensitization in adults (27-day protocol) and children (24-day protocol), achieving tolerance of 100–120 g beef daily. Sustained daily consumption is required to maintain desensitization. A pilot study demonstrated cow's milk containing 6 mg alpha-gal daily was safely tolerated over 3 years (macdougall2022themeatof pages 8-10). No FDA-approved OIT exists for AGS.
  • Nanoparticle immunotherapy: Nanoparticles encapsulating alpha-gal glycoprotein reduced Th2 cytokine production and IgE formation in prophylactic mouse models, though therapeutic administration showed only partial efficacy (propst2025alphagalsyndromeand pages 4-5).
  • Mast cell-directed therapy: A Phase 2 trial (NCT07526558) is testing ketotifen + cromolyn + fexofenadine vs. fexofenadine alone for post-tick bite illness including AGS (NCT07526558 chunk 1).
  • Alpha-gal knockout pork: Clinical trials are evaluating pork from GGTA1-knockout pigs as a safe food alternative and diagnostic control (NCT06268717, NCT07611435) (NCT06268717 chunk 1, NCT07611435 chunk 1).

Perioperative Management

Patients with AGS require careful perioperative medication review. Many common anesthetic and surgical products contain mammalian-derived alpha-gal, including heparin, gelatin-based hemostatic agents (surgifoam), gelatin capsules, propofol (glycerol content), and bioprosthetic heart valves (leder2024perioperativeconsiderationsin pages 3-5, leder2024perioperativeconsiderationsin pages 2-3, leder2024perioperativeconsiderationsin pages 1-2). Preoperative steroids and antihistamines are recommended before high-dose heparin exposure, and alternative anticoagulants (sodium citrate) should be considered (commins2020diagnosis&management pages 16-18, leder2024perioperativeconsiderationsin pages 2-3). 24–50% of AGS patients undergoing cardiac surgery with cardiopulmonary bypass experienced severe allergic reactions (leder2024perioperativeconsiderationsin pages 2-3). Intravenous formulations are generally safer than oral formulations due to fewer mammalian-derived fillers (leder2024perioperativeconsiderationsin pages 7-9).

Clinical Trials

The following table summarizes active and completed clinical trials for AGS:

Table (click to expand)
NCT ID Title Phase Status Sponsor Enrollment Key Design Features
NCT06268717 GI Alpha-Gal Study NA Completed University of North Carolina, Chapel Hill 30 Double-blind randomized crossover food challenge comparing pork with alpha-gal vs pork without alpha-gal; includes lactulose/C13 mannitol testing, transnasal upper endoscopy with GI biopsies, basophil activation, tryptase, and mRNA/pathology studies (NCT06268717 chunk 1, NCT06268717 chunk 2)
NCT04828317 Alpha-gal Pork Challenge NA Unknown University of Virginia 54 Pork challenge study in alpha-gal syndrome; interventional design evaluating clinical responses to pork exposure (clinical trial search result in prior tool output)
NCT07611435 Beginning to Assess an Appropriate CONtrol for Oral Food Challenges in Alpha-Gal Syndrome (CoFAR-13) - BeACON4AG Phase 2 Not yet recruiting National Institute of Allergy and Infectious Diseases (NIAID) 160 Multisite randomized double-blind crossover diagnostic trial; participants receive alpha-gal knockout pork and wild-type pork on separate visits to compare odds of positive double-blind food challenges and define AGS sub-phenotypes (NCT07611435 chunk 1, NCT07611435 chunk 2)
NCT07177729 The α-gal Syndrome - Investigating Immune Reactions to Tick Bites (ImmunoGal) Observational Recruiting Luxembourg Institute of Health 100 Prospective cohort enrolling participants within 48 hours of tick removal; longitudinal blood sampling, tick collection/PCR, serology, and multi-omics immune profiling to identify signatures associated with alpha-gal sensitization after tick bites (NCT07177729 chunk 1)
NCT07526558 Mast Cell Treatment in Post-tick Bite Illness (PTBI) Phase 2 Not yet recruiting University of North Carolina, Chapel Hill 50 Randomized double-blind parallel pilot trial testing ketotifen + cromolyn + fexofenadine versus fexofenadine alone for persistent mast cell activation symptoms after post-tick bite illness, including AGS (NCT07526558 chunk 1)

Table: This table summarizes the main clinical trials identified for alpha-gal syndrome and related post-tick bite illness. It is useful for quickly comparing study design, status, enrollment, and the main research focus of each trial.

13. Prevention

Primary Prevention

  • Tick bite avoidance: The most critical prevention strategy. Recommended measures include protective clothing treated with permethrin, prompt tick removal with specialized forceps, and use of tick repellents (vazrodrigues2022currentandfuture pages 6-7).
  • Public awareness: Provider knowledge of AGS remains limited; inclusion of AGS content in medical school curricula is recommended (Thompson et al. 2025).

Secondary Prevention

  • Early diagnosis: Clinicians should suspect AGS in patients with adult-onset atopy, idiopathic anaphylaxis, insect bite hypersensitivity, or delayed reactions to red meat (taylor2024intrinsicriskfactors pages 1-3).
  • Alpha-gal sIgE testing: Should be performed in at-risk individuals with compatible symptoms.
  • Dietary counseling: Dietician consultation recommended for identifying hidden alpha-gal ingredients in processed foods, supplements, and medications (propst2025alphagalsyndromeand pages 4-5).

Tertiary Prevention

14. Other Species / Natural Disease

Tick Species and Cross-Species Biology

Alpha-gal is widely expressed in non-primate mammals (including cows, pigs, sheep, deer), bacteria, and parasites including ticks (wilson2024tickbitesige pages 1-3). The alpha-gal epitope is synthesized by functional alpha-1,3-galactosyltransferase in these organisms. Tick galactosyltransferases are involved in synthesizing alpha-gal in tick tissues and saliva (cabezascruz2019environmentalandmolecular pages 1-2). N-glycome profiling and proteome analysis have demonstrated alpha-gal antigens in salivary gland extracts and saliva of A. americanum and Ixodes scapularis, but not in Amblyomma maculatum (sharma2024tickbiteinducedalphagal pages 1-2).

Zoonotic/Vector-Borne Considerations

AGS is fundamentally a vector-borne allergic disease. The sensitization pathway is unique in that it involves an arthropod vector (tick) but is not an infectious disease. The clinical syndrome is dependent on subsequent exposure to mammalian-derived products, making it a complex interface of ectoparasite biology and human immunology.

15. Model Organisms

AGKO Mouse Model

The primary animal model is the alpha-gal knockout (AGKO) mouse, which has a targeted disruption of alpha-1,3-galactosyltransferase and therefore cannot produce alpha-gal, mimicking the human condition (sharma2024tickbiteinducedalphagal pages 1-2). In this model: - A. americanum nymph infestation induced significant increases in total IgE, IgG1, and alpha-gal IgG1 antibody titers compared to A. maculatum-sensitized mice (sharma2024tickbiteinducedalphagal pages 1-2). - Pork challenge in A. americanum-sensitized AGKO mice led to body temperature decline (anaphylaxis-like response) (sharma2024tickbiteinducedalphagal pages 1-2). - Gene expression analysis revealed A. americanum bites direct mouse immunity toward Th2 polarization (sharma2024tickbiteinducedalphagal pages 1-2).

In Vitro Models

  • Humanized cell lines and primary cultures using human sera and novel human alpha-gal-specific IgE monoclonal antibodies are used to study allergic effector cell activation (kepley2025tickedoffallergic pages 1-2).
  • Nanoparticle immunotherapy has been tested in mouse models showing reduction in Th2 cytokines and alpha-gal-specific IgE with prophylactic treatment (choudhary2025singlecellmrnaanalysis pages 1-2).

Model Limitations

  • AGKO mice do not fully recapitulate all features of human AGS, particularly the delayed reaction kinetics and the complexity of human lipid metabolism.
  • Species-specific differences in tick-host interactions may limit translational applicability.

Summary of Key Ontology Terms

Key References

This report draws from 17 primary research publications and 4 clinical trial registrations, including comprehensive reviews in Allergy (Wilson et al. 2024), Journal of Immunology (Carson et al. 2022), ImmunoTargets and Therapy (Macdougall et al. 2022), Immunological Reviews (Platts-Mills et al. 2025), Frontiers in Immunology (Sharma et al. 2024; Choudhary & Commins 2025), and clinical data from the CDC-affiliated cohort study published in Allergy (Binder et al. 2023) and the case-control study in Annals of Allergy, Asthma & Immunology (Taylor et al. 2024).

References

  1. (wilson2024tickbitesige pages 1-3): Jeffrey M. Wilson, Loren Erickson, Michael Levin, Samuel M. Ailsworth, Scott P. Commins, and Thomas A. E. Platts‐Mills. Tick bites, ige to galactose-alpha-1,3-galactose and urticarial or anaphylactic reactions to mammalian meat: the alpha-gal syndrome. Allergy, 79:1440-1454, Jan 2024. URL: https://doi.org/10.1111/all.16003, doi:10.1111/all.16003. This article has 72 citations and is from a highest quality peer-reviewed journal.

  2. (macdougall2022themeatof pages 1-2): Jessica D Macdougall, Kevin O Thomas, and Onyinye I Iweala. The meat of the matter: understanding and managing alpha-gal syndrome. ImmunoTargets and Therapy, 11:37-54, Sep 2022. URL: https://doi.org/10.2147/itt.s276872, doi:10.2147/itt.s276872. This article has 71 citations.

  3. (vazrodrigues2022currentandfuture pages 1-2): Rita Vaz-Rodrigues, Lorena Mazuecos, and José de la Fuente. Current and future strategies for the diagnosis and treatment of the alpha-gal syndrome (ags). Journal of Asthma and Allergy, 15:957-970, Jul 2022. URL: https://doi.org/10.2147/jaa.s265660, doi:10.2147/jaa.s265660. This article has 70 citations and is from a peer-reviewed journal.

  4. (propst2025alphagalsyndromeand pages 1-2): Susan B. H. Propst and Dorothea K. Thompson. Alpha-gal syndrome and the gastrointestinal reaction: a narrative review. Frontiers in Allergy, Jan 2025. URL: https://doi.org/10.3389/falgy.2025.1535103, doi:10.3389/falgy.2025.1535103. This article has 13 citations and is from a peer-reviewed journal.

  5. (choudhary2025singlecellmrnaanalysis pages 1-2): Shailesh K. Choudhary and Scott P. Commins. Single-cell mrna analysis and surface marker expression profiling of circulating immune cells in humans with alpha-gal syndrome. Frontiers in Immunology, Sep 2025. URL: https://doi.org/10.3389/fimmu.2025.1629310, doi:10.3389/fimmu.2025.1629310. This article has 2 citations and is from a peer-reviewed journal.

  6. (NCT06268717 chunk 2): GI Alpha-Gal Study. University of North Carolina, Chapel Hill. 2023. ClinicalTrials.gov Identifier: NCT06268717

  7. (wilson2024tickbitesige pages 3-4): Jeffrey M. Wilson, Loren Erickson, Michael Levin, Samuel M. Ailsworth, Scott P. Commins, and Thomas A. E. Platts‐Mills. Tick bites, ige to galactose-alpha-1,3-galactose and urticarial or anaphylactic reactions to mammalian meat: the alpha-gal syndrome. Allergy, 79:1440-1454, Jan 2024. URL: https://doi.org/10.1111/all.16003, doi:10.1111/all.16003. This article has 72 citations and is from a highest quality peer-reviewed journal.

  8. (macdougall2022themeatof pages 2-4): Jessica D Macdougall, Kevin O Thomas, and Onyinye I Iweala. The meat of the matter: understanding and managing alpha-gal syndrome. ImmunoTargets and Therapy, 11:37-54, Sep 2022. URL: https://doi.org/10.2147/itt.s276872, doi:10.2147/itt.s276872. This article has 71 citations.

  9. (cabezascruz2019environmentalandmolecular pages 1-2): Alejandro Cabezas-Cruz, Adnan Hodžić, Patricia Román-Carrasco, Lourdes Mateos-Hernández, Georg Gerhard Duscher, Deepak Kumar Sinha, Wolfgang Hemmer, Ines Swoboda, Agustín Estrada-Peña, and José de la Fuente. Environmental and molecular drivers of the α-gal syndrome. Frontiers in Immunology, May 2019. URL: https://doi.org/10.3389/fimmu.2019.01210, doi:10.3389/fimmu.2019.01210. This article has 84 citations and is from a peer-reviewed journal.

  10. (kepley2025tickedoffallergic pages 1-2): Christopher L. Kepley, Yinghui Wang, Amy Yelton, Eva R. Siebert, and Onyinye I. Iweala. Ticked off: allergic effector cells in the pathogenesis of alpha-gal syndrome. Current Allergy and Asthma Reports, Nov 2025. URL: https://doi.org/10.1007/s11882-025-01237-2, doi:10.1007/s11882-025-01237-2. This article has 3 citations and is from a peer-reviewed journal.

  11. (taylor2024intrinsicriskfactors pages 6-8): Marissa L. Taylor, Gilbert J. Kersh, Johanna S. Salzer, Emma S. Jones, Alison M. Binder, Paige A. Armstrong, Shailesh K. Choudhary, Grace K. Commins, Claire L. Amelio, Brad J. Biggerstaff, Charles B. Beard, Lyle R. Petersen, and Scott P. Commins. Intrinsic risk factors for alpha-gal syndrome in a case-control study, 2019 to 2020. Annals of Allergy, Asthma & Immunology, 132:759-764.e2, Jun 2024. URL: https://doi.org/10.1016/j.anai.2024.01.029, doi:10.1016/j.anai.2024.01.029. This article has 23 citations.

  12. (macdougall2022themeatof pages 4-5): Jessica D Macdougall, Kevin O Thomas, and Onyinye I Iweala. The meat of the matter: understanding and managing alpha-gal syndrome. ImmunoTargets and Therapy, 11:37-54, Sep 2022. URL: https://doi.org/10.2147/itt.s276872, doi:10.2147/itt.s276872. This article has 71 citations.

  13. (taylor2024intrinsicriskfactors pages 1-3): Marissa L. Taylor, Gilbert J. Kersh, Johanna S. Salzer, Emma S. Jones, Alison M. Binder, Paige A. Armstrong, Shailesh K. Choudhary, Grace K. Commins, Claire L. Amelio, Brad J. Biggerstaff, Charles B. Beard, Lyle R. Petersen, and Scott P. Commins. Intrinsic risk factors for alpha-gal syndrome in a case-control study, 2019 to 2020. Annals of Allergy, Asthma & Immunology, 132:759-764.e2, Jun 2024. URL: https://doi.org/10.1016/j.anai.2024.01.029, doi:10.1016/j.anai.2024.01.029. This article has 23 citations.

  14. (taylor2024intrinsicriskfactors pages 5-6): Marissa L. Taylor, Gilbert J. Kersh, Johanna S. Salzer, Emma S. Jones, Alison M. Binder, Paige A. Armstrong, Shailesh K. Choudhary, Grace K. Commins, Claire L. Amelio, Brad J. Biggerstaff, Charles B. Beard, Lyle R. Petersen, and Scott P. Commins. Intrinsic risk factors for alpha-gal syndrome in a case-control study, 2019 to 2020. Annals of Allergy, Asthma & Immunology, 132:759-764.e2, Jun 2024. URL: https://doi.org/10.1016/j.anai.2024.01.029, doi:10.1016/j.anai.2024.01.029. This article has 23 citations.

  15. (binder2023clinicalandlaboratory pages 1-1): Alison M. Binder, Dena Cherry‐Brown, Brad J. Biggerstaff, Emma S. Jones, Claire L. Amelio, Charles B. Beard, Lyle R. Petersen, Gilbert J. Kersh, Scott P. Commins, and Paige A. Armstrong. Clinical and laboratory features of patients diagnosed with alpha‐gal syndrome—2010–2019. Allergy, 78:477-487, Oct 2023. URL: https://doi.org/10.1111/all.15539, doi:10.1111/all.15539. This article has 42 citations and is from a highest quality peer-reviewed journal.

  16. (nalcacı2024mysteriousallergycaused pages 6-7): Muhammed Nalçacı. Mysterious allergy caused by tick bite: alpha-gal syndrome. Turkiye parazitolojii dergisi, 48 3:195-207, Oct 2024. URL: https://doi.org/10.4274/tpd.galenos.2024.97720, doi:10.4274/tpd.galenos.2024.97720. This article has 7 citations.

  17. (binder2023clinicalandlaboratory pages 2-2): Alison M. Binder, Dena Cherry‐Brown, Brad J. Biggerstaff, Emma S. Jones, Claire L. Amelio, Charles B. Beard, Lyle R. Petersen, Gilbert J. Kersh, Scott P. Commins, and Paige A. Armstrong. Clinical and laboratory features of patients diagnosed with alpha‐gal syndrome—2010–2019. Allergy, 78:477-487, Oct 2023. URL: https://doi.org/10.1111/all.15539, doi:10.1111/all.15539. This article has 42 citations and is from a highest quality peer-reviewed journal.

  18. (propst2025alphagalsyndromeand pages 2-3): Susan B. H. Propst and Dorothea K. Thompson. Alpha-gal syndrome and the gastrointestinal reaction: a narrative review. Frontiers in Allergy, Jan 2025. URL: https://doi.org/10.3389/falgy.2025.1535103, doi:10.3389/falgy.2025.1535103. This article has 13 citations and is from a peer-reviewed journal.

  19. (carson2022where’sthebeef? pages 3-4): Audrey S. Carson, Aliyah Gardner, and Onyinye I. Iweala. Where’s the beef? : understanding allergic responses to red meat in alpha-gal syndrome. Journal of immunology (Baltimore, Md. : 1950), 208:267-277, Jan 2022. URL: https://doi.org/10.4049/jimmunol.2100712, doi:10.4049/jimmunol.2100712. This article has 47 citations.

  20. (vazrodrigues2022currentandfuture pages 6-7): Rita Vaz-Rodrigues, Lorena Mazuecos, and José de la Fuente. Current and future strategies for the diagnosis and treatment of the alpha-gal syndrome (ags). Journal of Asthma and Allergy, 15:957-970, Jul 2022. URL: https://doi.org/10.2147/jaa.s265660, doi:10.2147/jaa.s265660. This article has 70 citations and is from a peer-reviewed journal.

  21. (macdougall2022themeatof pages 10-11): Jessica D Macdougall, Kevin O Thomas, and Onyinye I Iweala. The meat of the matter: understanding and managing alpha-gal syndrome. ImmunoTargets and Therapy, 11:37-54, Sep 2022. URL: https://doi.org/10.2147/itt.s276872, doi:10.2147/itt.s276872. This article has 71 citations.

  22. (nalcacı2024mysteriousallergycaused pages 1-2): Muhammed Nalçacı. Mysterious allergy caused by tick bite: alpha-gal syndrome. Turkiye parazitolojii dergisi, 48 3:195-207, Oct 2024. URL: https://doi.org/10.4274/tpd.galenos.2024.97720, doi:10.4274/tpd.galenos.2024.97720. This article has 7 citations.

  23. (propst2025alphagalsyndromeand pages 7-8): Susan B. H. Propst and Dorothea K. Thompson. Alpha-gal syndrome and the gastrointestinal reaction: a narrative review. Frontiers in Allergy, Jan 2025. URL: https://doi.org/10.3389/falgy.2025.1535103, doi:10.3389/falgy.2025.1535103. This article has 13 citations and is from a peer-reviewed journal.

  24. (leder2024perioperativeconsiderationsin pages 3-5): John Leder, Anna Diederich, Bhavik Patel, Mark Bowie, Christian M Renwick, and Venkat Mangunta. Perioperative considerations in alpha-gal syndrome: a review. Cureus, Jan 2024. URL: https://doi.org/10.7759/cureus.53208, doi:10.7759/cureus.53208. This article has 16 citations.

  25. (NCT07611435 chunk 1): Beginning to Assess an Appropriate CONtrol for Oral Food Challenges in Alpha-Gal Syndrome (CoFAR-13) - BeACON4AG. National Institute of Allergy and Infectious Diseases (NIAID). 2026. ClinicalTrials.gov Identifier: NCT07611435

  26. (macdougall2022themeatof pages 11-13): Jessica D Macdougall, Kevin O Thomas, and Onyinye I Iweala. The meat of the matter: understanding and managing alpha-gal syndrome. ImmunoTargets and Therapy, 11:37-54, Sep 2022. URL: https://doi.org/10.2147/itt.s276872, doi:10.2147/itt.s276872. This article has 71 citations.

  27. (carson2022where’sthebeef? pages 1-3): Audrey S. Carson, Aliyah Gardner, and Onyinye I. Iweala. Where’s the beef? : understanding allergic responses to red meat in alpha-gal syndrome. Journal of immunology (Baltimore, Md. : 1950), 208:267-277, Jan 2022. URL: https://doi.org/10.4049/jimmunol.2100712, doi:10.4049/jimmunol.2100712. This article has 47 citations.

  28. (choudhary2025singlecellmrnaanalysis pages 14-17): Shailesh K. Choudhary and Scott P. Commins. Single-cell mrna analysis and surface marker expression profiling of circulating immune cells in humans with alpha-gal syndrome. Frontiers in Immunology, Sep 2025. URL: https://doi.org/10.3389/fimmu.2025.1629310, doi:10.3389/fimmu.2025.1629310. This article has 2 citations and is from a peer-reviewed journal.

  29. (commins2020diagnosis&management pages 16-18): Scott P. Commins. Diagnosis & management of alpha-gal syndrome: lessons from 2,500 patients. Jul 2020. URL: https://doi.org/10.1080/1744666x.2020.1782745, doi:10.1080/1744666x.2020.1782745. This article has 114 citations and is from a peer-reviewed journal.

  30. (sharma2024tickbiteinducedalphagal pages 1-2): Surendra Raj Sharma, Shailesh K. Choudhary, Julia Vorobiov, Scott P. Commins, and Shahid Karim. Tick bite-induced alpha-gal syndrome and immunologic responses in an alpha-gal deficient murine model. Frontiers in Immunology, Feb 2024. URL: https://doi.org/10.3389/fimmu.2023.1336883, doi:10.3389/fimmu.2023.1336883. This article has 28 citations and is from a peer-reviewed journal.

  31. (platts‐mills2025theimmunologyof pages 6-8): Thomas A. E. Platts‐Mills, Roopesh Singh Gangwar, Lisa Workman, and Jeffrey M. Wilson. The immunology of alpha‐gal syndrome: history, tick bites, ige, and delayed anaphylaxis to mammalian meat. Immunological Reviews, Jun 2025. URL: https://doi.org/10.1111/imr.70035, doi:10.1111/imr.70035. This article has 19 citations and is from a domain leading peer-reviewed journal.

  32. (platts‐mills2025theimmunologyof pages 11-13): Thomas A. E. Platts‐Mills, Roopesh Singh Gangwar, Lisa Workman, and Jeffrey M. Wilson. The immunology of alpha‐gal syndrome: history, tick bites, ige, and delayed anaphylaxis to mammalian meat. Immunological Reviews, Jun 2025. URL: https://doi.org/10.1111/imr.70035, doi:10.1111/imr.70035. This article has 19 citations and is from a domain leading peer-reviewed journal.

  33. (branicka2025alphagalsyndrome—aseries pages 4-6): Olga Branicka, Lesia Rozłucka, Radosław Gawlik, and Joanna Glück. Alpha-gal syndrome—a series of cases with different clinical pictures. International Journal of Molecular Sciences, 26:8601, Sep 2025. URL: https://doi.org/10.3390/ijms26178601, doi:10.3390/ijms26178601. This article has 0 citations.

  34. (carson2022where’sthebeef? pages 9-11): Audrey S. Carson, Aliyah Gardner, and Onyinye I. Iweala. Where’s the beef? : understanding allergic responses to red meat in alpha-gal syndrome. Journal of immunology (Baltimore, Md. : 1950), 208:267-277, Jan 2022. URL: https://doi.org/10.4049/jimmunol.2100712, doi:10.4049/jimmunol.2100712. This article has 47 citations.

  35. (carson2022where’sthebeef? pages 8-9): Audrey S. Carson, Aliyah Gardner, and Onyinye I. Iweala. Where’s the beef? : understanding allergic responses to red meat in alpha-gal syndrome. Journal of immunology (Baltimore, Md. : 1950), 208:267-277, Jan 2022. URL: https://doi.org/10.4049/jimmunol.2100712, doi:10.4049/jimmunol.2100712. This article has 47 citations.

  36. (kepley2025tickedoffallergic pages 7-8): Christopher L. Kepley, Yinghui Wang, Amy Yelton, Eva R. Siebert, and Onyinye I. Iweala. Ticked off: allergic effector cells in the pathogenesis of alpha-gal syndrome. Current Allergy and Asthma Reports, Nov 2025. URL: https://doi.org/10.1007/s11882-025-01237-2, doi:10.1007/s11882-025-01237-2. This article has 3 citations and is from a peer-reviewed journal.

  37. (carson2022where’sthebeef? pages 6-8): Audrey S. Carson, Aliyah Gardner, and Onyinye I. Iweala. Where’s the beef? : understanding allergic responses to red meat in alpha-gal syndrome. Journal of immunology (Baltimore, Md. : 1950), 208:267-277, Jan 2022. URL: https://doi.org/10.4049/jimmunol.2100712, doi:10.4049/jimmunol.2100712. This article has 47 citations.

  38. (choudhary2025singlecellmrnaanalysis pages 17-18): Shailesh K. Choudhary and Scott P. Commins. Single-cell mrna analysis and surface marker expression profiling of circulating immune cells in humans with alpha-gal syndrome. Frontiers in Immunology, Sep 2025. URL: https://doi.org/10.3389/fimmu.2025.1629310, doi:10.3389/fimmu.2025.1629310. This article has 2 citations and is from a peer-reviewed journal.

  39. (kuravi2022allergicresponseto pages 1-2): Kasinath V. Kuravi, Lori T. Sorrells, Joseph R. Nellis, Farzana Rahman, Anneke H. Walters, Robert G. Matheny, Shailesh K. Choudhary, David L. Ayares, Scott P. Commins, John R. Bianchi, and Joseph W. Turek. Allergic response to medical products in patients with alpha-gal syndrome. The Journal of Thoracic and Cardiovascular Surgery, 164:e411-e424, Dec 2022. URL: https://doi.org/10.1016/j.jtcvs.2021.03.100, doi:10.1016/j.jtcvs.2021.03.100. This article has 72 citations.

  40. (kuravi2022allergicresponseto pages 6-9): Kasinath V. Kuravi, Lori T. Sorrells, Joseph R. Nellis, Farzana Rahman, Anneke H. Walters, Robert G. Matheny, Shailesh K. Choudhary, David L. Ayares, Scott P. Commins, John R. Bianchi, and Joseph W. Turek. Allergic response to medical products in patients with alpha-gal syndrome. The Journal of Thoracic and Cardiovascular Surgery, 164:e411-e424, Dec 2022. URL: https://doi.org/10.1016/j.jtcvs.2021.03.100, doi:10.1016/j.jtcvs.2021.03.100. This article has 72 citations.

  41. (choudhary2025singlecellmrnaanalysis pages 4-5): Shailesh K. Choudhary and Scott P. Commins. Single-cell mrna analysis and surface marker expression profiling of circulating immune cells in humans with alpha-gal syndrome. Frontiers in Immunology, Sep 2025. URL: https://doi.org/10.3389/fimmu.2025.1629310, doi:10.3389/fimmu.2025.1629310. This article has 2 citations and is from a peer-reviewed journal.

  42. (choudhary2025singlecellmrnaanalysis pages 8-11): Shailesh K. Choudhary and Scott P. Commins. Single-cell mrna analysis and surface marker expression profiling of circulating immune cells in humans with alpha-gal syndrome. Frontiers in Immunology, Sep 2025. URL: https://doi.org/10.3389/fimmu.2025.1629310, doi:10.3389/fimmu.2025.1629310. This article has 2 citations and is from a peer-reviewed journal.

  43. (binder2023clinicalandlaboratory pages 8-8): Alison M. Binder, Dena Cherry‐Brown, Brad J. Biggerstaff, Emma S. Jones, Claire L. Amelio, Charles B. Beard, Lyle R. Petersen, Gilbert J. Kersh, Scott P. Commins, and Paige A. Armstrong. Clinical and laboratory features of patients diagnosed with alpha‐gal syndrome—2010–2019. Allergy, 78:477-487, Oct 2023. URL: https://doi.org/10.1111/all.15539, doi:10.1111/all.15539. This article has 42 citations and is from a highest quality peer-reviewed journal.

  44. (binder2023clinicalandlaboratory pages 2-3): Alison M. Binder, Dena Cherry‐Brown, Brad J. Biggerstaff, Emma S. Jones, Claire L. Amelio, Charles B. Beard, Lyle R. Petersen, Gilbert J. Kersh, Scott P. Commins, and Paige A. Armstrong. Clinical and laboratory features of patients diagnosed with alpha‐gal syndrome—2010–2019. Allergy, 78:477-487, Oct 2023. URL: https://doi.org/10.1111/all.15539, doi:10.1111/all.15539. This article has 42 citations and is from a highest quality peer-reviewed journal.

  45. (NCT06268717 chunk 1): GI Alpha-Gal Study. University of North Carolina, Chapel Hill. 2023. ClinicalTrials.gov Identifier: NCT06268717

  46. (macdougall2022themeatof pages 7-8): Jessica D Macdougall, Kevin O Thomas, and Onyinye I Iweala. The meat of the matter: understanding and managing alpha-gal syndrome. ImmunoTargets and Therapy, 11:37-54, Sep 2022. URL: https://doi.org/10.2147/itt.s276872, doi:10.2147/itt.s276872. This article has 71 citations.

  47. (macdougall2022themeatof pages 8-10): Jessica D Macdougall, Kevin O Thomas, and Onyinye I Iweala. The meat of the matter: understanding and managing alpha-gal syndrome. ImmunoTargets and Therapy, 11:37-54, Sep 2022. URL: https://doi.org/10.2147/itt.s276872, doi:10.2147/itt.s276872. This article has 71 citations.

  48. (propst2025alphagalsyndromeand pages 4-5): Susan B. H. Propst and Dorothea K. Thompson. Alpha-gal syndrome and the gastrointestinal reaction: a narrative review. Frontiers in Allergy, Jan 2025. URL: https://doi.org/10.3389/falgy.2025.1535103, doi:10.3389/falgy.2025.1535103. This article has 13 citations and is from a peer-reviewed journal.

  49. (vazrodrigues2022currentandfuture pages 7-8): Rita Vaz-Rodrigues, Lorena Mazuecos, and José de la Fuente. Current and future strategies for the diagnosis and treatment of the alpha-gal syndrome (ags). Journal of Asthma and Allergy, 15:957-970, Jul 2022. URL: https://doi.org/10.2147/jaa.s265660, doi:10.2147/jaa.s265660. This article has 70 citations and is from a peer-reviewed journal.

  50. (NCT07526558 chunk 1): Mast Cell Treatment in Post-tick Bite Illness (PTBI). University of North Carolina, Chapel Hill. 2026. ClinicalTrials.gov Identifier: NCT07526558

  51. (leder2024perioperativeconsiderationsin pages 2-3): John Leder, Anna Diederich, Bhavik Patel, Mark Bowie, Christian M Renwick, and Venkat Mangunta. Perioperative considerations in alpha-gal syndrome: a review. Cureus, Jan 2024. URL: https://doi.org/10.7759/cureus.53208, doi:10.7759/cureus.53208. This article has 16 citations.

  52. (leder2024perioperativeconsiderationsin pages 1-2): John Leder, Anna Diederich, Bhavik Patel, Mark Bowie, Christian M Renwick, and Venkat Mangunta. Perioperative considerations in alpha-gal syndrome: a review. Cureus, Jan 2024. URL: https://doi.org/10.7759/cureus.53208, doi:10.7759/cureus.53208. This article has 16 citations.

  53. (leder2024perioperativeconsiderationsin pages 7-9): John Leder, Anna Diederich, Bhavik Patel, Mark Bowie, Christian M Renwick, and Venkat Mangunta. Perioperative considerations in alpha-gal syndrome: a review. Cureus, Jan 2024. URL: https://doi.org/10.7759/cureus.53208, doi:10.7759/cureus.53208. This article has 16 citations.

  54. (NCT07611435 chunk 2): Beginning to Assess an Appropriate CONtrol for Oral Food Challenges in Alpha-Gal Syndrome (CoFAR-13) - BeACON4AG. National Institute of Allergy and Infectious Diseases (NIAID). 2026. ClinicalTrials.gov Identifier: NCT07611435

  55. (NCT07177729 chunk 1): The α-gal Syndrome - Investigating Immune Reactions to Tick Bites. Luxembourg Institute of Health. 2025. ClinicalTrials.gov Identifier: NCT07177729

Artifacts